CN104435000A - Application of lactic acid bacteria for treating bronchial asthma - Google Patents
Application of lactic acid bacteria for treating bronchial asthma Download PDFInfo
- Publication number
- CN104435000A CN104435000A CN201410634746.8A CN201410634746A CN104435000A CN 104435000 A CN104435000 A CN 104435000A CN 201410634746 A CN201410634746 A CN 201410634746A CN 104435000 A CN104435000 A CN 104435000A
- Authority
- CN
- China
- Prior art keywords
- group
- bronchial asthma
- lactic acid
- acid bacteria
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Abstract
The invention belongs to the technical field of biomedicines and particularly relates to a method for treating bronchial asthma by virtue of lactic acid bacteria, which is used for clinically treating patients with bronchial asthma caused by various reasons. For bronchial asthma caused by biological allergens and non-biological allergens, lactic acid bacteria can be used in the treatment process to stimulate the body to generate antibodies so as to adjust immune response of a human body. The lactic acid bacteria have the effects of resisting inflammatory reaction and reducing smooth muscle hypertrophy so as to alleviate attack and occurrence of asthma.
Description
Technical field
The invention discloses a kind of method of lactobacillus in Treating Bronchial Asthma, belong to biomedicine field.
Background technology
Lactobacillus (lactic acid bacteria, LAB) is that a class can utilize fermentable carbohydrate to produce the common name of the antibacterial of a large amount of lactic acid.This bacterioid is very extensive in distributed in nature, has abundant species diversity.They are not only research classification, biochemistry, heredity, molecular biology and engineered ideal material, there is important learning value in theory, and also high with human lives's closely-related key areas using value at industry, farming and animal husbandry, food and medicine etc.Wherein the overwhelming majority is all requisite in human body and has the flora of important physiological function, and it is extensively present in the intestinal of human body.Be proved at present, enteral lactobacillus and good health and a long life have very close relationship.
Lactobacillus can control toxins in human body level, and the liver protecting also strengthens removing toxic substances, the functions of expelling toxin of liver.The phagocytosis of lactobacillus and the obvious activating macrophage of bacillus bifidus one side energy, on the other hand because it at intestinal colonisation, can be equivalent to natural active immunity.They can also stimulate peritoneal macrophages, induce generation interferon, promote cell division, produce antibody and promote cellular immunization etc., the non-specific and specific immune response of energy enhancing body, the resistance against diseases of raising body.After the oral lactobacillus of the mankind, to the galactoside enzymatic activity of huge fine jade cell, the activate the phagocytic capacity etc. of macrophage, there is significant activation and facilitation.When foreign body invades body, immunocyte is activated by lactobacillus, enhances body produces antibody effect to foreign body.Why lactobacillus has the effect stimulating body to produce antibody, that the lymphocyte accepting to stimulate by lymph node, mucous membrane irritation lymphocyte due to thalline is recycled in blood flow by mesenteric lymph node (MIN) again, and the whole body that distributes, thus regulate the immunne response of body.Helper T cell (Th1/Th2) cell proportion is unbalance is one of Pathogenesy of Asthma.Interleukin 12 (L-12), by conjunction with L-12 receptor, improves IFN-γ (IFN-γ) content and becomes the principal element improving Th1 emiocytosis.
Summary of the invention:
The invention discloses a kind of method of lactobacillus in Treating Bronchial Asthma, be used for the treatment of the bronchial asthma that a variety of causes causes.The present invention proves a kind of method of lactobacillus in Treating Bronchial Asthma by following experiment.50 mices are divided into model control group (A group), PBS collunarium group (B group), wild mushroom collunarium group (C group), restructuring L-12 (rL-12) collunarium group (D group), engineering bacteria collunarium group (E group) by random digits table, often organize 10.Except A group, each group mice was at the 1st, 7,14 day lumbar injection OVA (100 μ g/015ml), and 20 ~ 26d sucks 2%OVA every day.B, C, E group gave PBS, the wild lactobacillus suspension of plasmid-free and contains each 10 μ l of L-12 plasmid engineering bacterium liquid at the 1st, 2,3,14,19,20,21 day, D group the 20th, 21,22 days every nasal cavities give 3ng rL-12, and the 28th day label taking originally.Enter
every tradeobserve for learning: record 20th ~ 26 days every mice sneeze, grab nose number of times and asthma degree: without sneeze: 0 point; <4 time: 1 point; 4 ~ 10 times: 2 points; >11 time: 3 points.Without grabbing nose: 0 point; Slightly grab nose: 1 point; Frequently grab nose: 2 points; Grab nose more than: 3 points.Without panting: 0 point; Rapid breathing: 1 point; Obviously pant: 2 points; Pant lethal: 3 points.Pathologic and cytokine assay: the 28th day mice opens breast and observe mice lungs after anesthesia, and ligation is got left lung sections and done hematoxylin 2 Yihong (HE) dyeing.Flushing right lung obtains bronchovesicular perfusate (BALF), and centrifugal transfer supernatant is to be measured afterwards.In BALF, cell calculates total cellular score after precipitation, separately gets smear and makes Wright's staining, (× 10) several 500 cells under mirror, calculates eosinophilic granulocyte (EOS) percentage ratio, takes advantage of percentage ratio and EOS absolute number with total cellular score.
Detailed description of the invention
Example below will illustrate operational approach of the present invention, but can not as limitation of the invention.
The present invention proved the effect of lactobacillus in Treating Bronchial Asthma by following experiment: by 6 ~ 8 weeks 50 cleaning grade mices, body weight 18 ~ 25g, model control group (A group), PBS collunarium group (B group), wild mushroom collunarium group (C group), restructuring L-12 (rL-12) collunarium group (D group) is divided into by random digits table, engineering bacteria collunarium group (E group), often organizes 10.Except A group, each group mice was at the 1st, 7,14 day lumbar injection ovalbumin (OVA) 100 μ g/0.5ml, and 20 ~ 26d sucks 2%OVA every day.B, C, E group gave phosphate buffer (PBS), the wild lactobacillus suspension of plasmid-free and contains each 10 μ l of L-12 plasmid engineering bacterium liquid at the 1st, 2,3,14,19,20,21 day, D group the 20th, 21,22 days, every nasal cavity gives 3ng rL-12, and the 28th day label taking originally.
1 animal behavioral study: record 20th ~ 26 days every mice sneeze, grab nose number of times and asthma degree.Without sneeze: 0 point; <4 time: 1 point; 4 ~ 10 times: 2 points; >11 time: 3 points.Without grabbing nose: 0 point; Slightly grab nose: 1 point; Frequently grab nose: 2 points; Grab nose more than: 3 points.Without panting: 0 point; Rapid breathing: 1 point; Obviously pant: 2 points; Pant lethal: 3 points.A group mice is without exception; B, C group mice have in various degree dysphoria, sneeze, grab nose, wherein 5 (3 in B group, 2 in C group) merge rapid breathing, abdominal muscle spasm, gatism, and every mice general comment is divided into 6 ~ 8 points; D, E group mice occasionally has sneeze, grabs nose, all the other Non Apparent Abnormalities, and every mice general comment is divided into 1 ~ 3 point.Experiment proves, after applying lactobacillus, the behavior of mice is comparatively quiet, does not have the performance of obvious asthma, represents that lactobacillus serves certain antagonism in the outbreak of bronchial asthma.
2 pathologics are observed: the 28th day mice opens breast and observe mice lungs after anesthesia, and ligation is got left lung sections and done hematoxylin 2 Yihong (HE) dyeing.Perusal A group mouse lung tissue is normal, and B, C group mice lungs compare with A group that volume increases, there is irregular congested district surperficial swelling, many places, and tangent plane foam has exudate.Om observation display A group mouse bronchial mucosa is normal, B, C group mouse bronchial smooth muscle hypertrophy, tube wall inflammatory cell infiltration.HE coloration result display B, C group mouse lung local has lamellar hemorrhage, in having around bronchus and blood vessel, the chronic inflammatory cell infiltration such as severe lymphocyte, EOS.D, E group compares pathological changes with B, C group and obviously alleviates, and has mild inflammatory cellular infiltration around blood vessel, substantially close to A group.Find after pathological observation, the mouse lung tissue pathological changes after application lactobacillus obviously alleviates, and substantially close to normal group, proves that lactobacillus has opposing inflammatory reaction, alleviates the effect of the hypertrophy of smooth muscle, and then alleviates outbreak and the generation of asthma.
3 cytokine assay: flushing right lung obtains bronchovesicular perfusate (BALF), and centrifugal transfer supernatant is to be measured afterwards.In BALF, cell calculates total cellular score after precipitation, separately gets smear and makes Wright's staining, (× 10) several 500 cells under mirror, calculates eosinophilic granulocyte (EOS) percentage ratio, takes advantage of percentage ratio and EOS absolute number with total cellular score.The horizontal B of EOS and L-4 in BALF, component C not and A, D, E group comparing difference all have statistical significance (the equal <0.01 of P); IFN-γ horizontal B, C group and A, D, E group comparing difference also have statistical significance (the equal <0.01 of P,
table 1).L-12 protein expression: L-12 can in NZ9000 effective expression, judge that NZ9000 can produce and secrete the L-12 of about 80pg/ml.Prove by experiment, lactobacillus can alleviate the hypertrophy effect of bronchial smooth muscle, reduces inflammatory reaction.
table 1in 5 groups of mice BALF, EOS, L-4, IFN2 γ compares (x ± s)
Note: compare * P<0.01 with A group; #P<0.01 is compared with B group; △ P<0.01 is compared with C group
Example one
Clinically because of the Bronchial Asthmas that a variety of causes causes, can apply lactobacillus over the course for the treatment of, application process is oral 5ml/ days.
Claims (2)
1. a kind of method of lactobacillus in Treating Bronchial Asthma.
2. a kind of method of lactobacillus according to claim 1 in Treating Bronchial Asthma, is characterized in that: clinically because of the Bronchial Asthmas that a variety of causes causes, can apply lactobacillus over the course for the treatment of, and application process is oral 5ml/ days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410634746.8A CN104435000A (en) | 2014-11-12 | 2014-11-12 | Application of lactic acid bacteria for treating bronchial asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410634746.8A CN104435000A (en) | 2014-11-12 | 2014-11-12 | Application of lactic acid bacteria for treating bronchial asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104435000A true CN104435000A (en) | 2015-03-25 |
Family
ID=52882262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410634746.8A Pending CN104435000A (en) | 2014-11-12 | 2014-11-12 | Application of lactic acid bacteria for treating bronchial asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435000A (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CN110520119A (en) * | 2017-04-24 | 2019-11-29 | 慧鼻通有限责任公司 | Oral micropopulation promotes composition and its application method |
| US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
| US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
| US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
| US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102604854A (en) * | 2010-12-08 | 2012-07-25 | 台湾东洋药品工业股份有限公司 | Novel lactic acid bacterium strains and application thereof to adjustment of immune reaction |
-
2014
- 2014-11-12 CN CN201410634746.8A patent/CN104435000A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102604854A (en) * | 2010-12-08 | 2012-07-25 | 台湾东洋药品工业股份有限公司 | Novel lactic acid bacterium strains and application thereof to adjustment of immune reaction |
Non-Patent Citations (2)
| Title |
|---|
| 李理: "乳酸菌对尘螨致敏哮喘小鼠模型的免疫调节作用", 《医学研究生学报》 * |
| 杨光等: "乳酸菌表达的白细胞介素12对支气管哮喘小鼠的免疫调节", 《中华结核和呼吸杂志》 * |
Cited By (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
| US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
| US11414463B2 (en) | 2013-04-10 | 2022-08-16 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US10973872B2 (en) | 2014-12-23 | 2021-04-13 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
| US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11273185B2 (en) | 2015-06-15 | 2022-03-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11040075B2 (en) | 2015-06-15 | 2021-06-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11331352B2 (en) | 2015-06-15 | 2022-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11389493B2 (en) | 2015-06-15 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744167B2 (en) | 2015-06-15 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10780134B2 (en) | 2015-06-15 | 2020-09-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11433106B2 (en) | 2015-06-15 | 2022-09-06 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10864236B2 (en) | 2015-06-15 | 2020-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11058732B2 (en) | 2015-11-20 | 2021-07-13 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10960031B2 (en) | 2016-07-13 | 2021-03-30 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10967010B2 (en) | 2016-07-13 | 2021-04-06 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
| US10898526B2 (en) | 2016-12-12 | 2021-01-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10543238B2 (en) | 2016-12-12 | 2020-01-28 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CN110520119A (en) * | 2017-04-24 | 2019-11-29 | 慧鼻通有限责任公司 | Oral micropopulation promotes composition and its application method |
| US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11376284B2 (en) | 2017-05-22 | 2022-07-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11382936B2 (en) | 2017-05-22 | 2022-07-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435000A (en) | Application of lactic acid bacteria for treating bronchial asthma | |
| JP6527280B2 (en) | Compositions comprising bacterial strains | |
| Dinulos et al. | Keratinocyte expression of human β defensin 2 following bacterial infection: role in cutaneous host defense | |
| Vadalasetty et al. | Influence of silver nanoparticles on growth and health of broiler chickens after infection with Campylobacter jejuni | |
| Yan et al. | Probiotics and immune health | |
| CN103989713B (en) | Immunopotentiating composition and its manufacture method | |
| TWI607758B (en) | Lactobacillus paracasei strain gmnl-653 and composition having the same for improving psoriasis symptoms | |
| EP2722386B1 (en) | Crushed cells and composition thereof | |
| CN102048158A (en) | Health-care food with effect of improving immunity and preparation method thereof | |
| Cano et al. | Killing of Paracoccidioides brasiliensis conidia by pulmonary macrophages and the effect of cytokines | |
| CN107802831A (en) | One kind inactivation lactic acid bacteria vaccine adjuvant | |
| Hao et al. | The biological regulatory activities of Flammulina velutipes polysaccharide in mice intestinal microbiota, immune repertoire and heart transcriptome | |
| CN103704529B (en) | A kind of Broiler chicks feed addictive and preparation thereof, using method | |
| Pichler et al. | The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model | |
| Guo et al. | Lacticaseibacillus rhamnosus reduces the pathogenicity of Escherichia coli in chickens | |
| CN111544456A (en) | Probiotic formula and application thereof | |
| CN103948610B (en) | A kind of immunostimulant and application thereof | |
| Roudbary et al. | Immunomodulatory effect of β-glucan on peritoneal macrophages of BABL/c mice | |
| WO2008101450A1 (en) | Probiotic, gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in humans | |
| Chaicumpa et al. | Studies in vitro on the reaction of peritoneal exudate cells from mice immune to infection with Nematospiroides dubius with the infective third stage larvae of this parasite | |
| Jiang et al. | Commensal enteric bacteria lipopolysaccharide impairs host defense against disseminated Candida albicans fungal infection | |
| Ştefănut et al. | Effects of probiotics, prebiotics and synbiotics on some hematological and microbiological parameters in laboratory mice. | |
| CN2335652Y (en) | Influenza preventing and treating health mask | |
| Satheesh et al. | Effect of feeding Pediococcus acidilactici on performance of broiler chicken and microstructures of intestinal villus | |
| Zeeuwen et al. | The skin microbiota |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150325 |